InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, releases an integration of CYTOCON DB and fIVE DB with Heta. Now Heta format is upgraded to allow direct query to databases from the QSP model code without working with database websites.
CYTOCON DB is an online database of human baseline concentrations of cytokines and cells measured in different tissues of healthy subjects and patients suffering from various pathologies. Heta format developed for QSP models encoding into Excel table was upgraded in such a way to allow results of the query to CYTOCON DB to appear in the QSP model code directly in the section describing species included in the model in form of weighted mean and weighted standard deviations for cells and cytokines concentrations. Moreover, results of the query to fIVE DB now appear in the QSP model code directly in the section describing initialization of model parameters in form of weighted mean and minimal and maximal values of model parameters (kbase, Emax/IC50, EC50/IC50, etc.) fIVE DB is an InSysBio project for in vitro experiments information collection and processing.
Such integration of CYTOCON DB and fIVE DB with Heta enables QSP modelers:
About Heta
The Heta Project is an open-source initiative dedicated to transforming the landscape of pharmacology and systems biology modeling. By developing a unified infrastructure and best practices, we empower researchers and practitioners to create dynamic quantitative models with ease and efficiency. Heta is a software tool for the development of large-scale QSP models and compilation into simulation formats.
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | May 2025 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
| |||
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
|
12
|
13
|
14
|
15
1.
15 May 2025 15:07
15th InSysBio’s Annual Internal Scientific Meeting
InSysBio held its 15th Annual Internal Scientific Meeting. The Meeting traditionally passed in warm, friendly atmosphere and the discussion was efficient and uniting.
|
16
|
17
|
18
|
|
19
|
20
|
21
1.
21 May 2025 16:55
InSysBio to take part in PAGE 2025
InSysBio announces its participation in the Thirty-third PAGE Meeting which is to be held from 4-6 June, 2025, at the Thessaloniki Concert Hall in Thessaloniki, Greece. InSysBio team is going to present its QSP modeling services & software to optimize drug development at the Booth #10 in the upper foyer and 2 posters in frames of the Meeting
|
22
|
23
|
24
|
25
|
|
26
|
27
|
28
|
29
|
30
1.
30 May 2025 15:23
InSysBio to publish the new article in CPT: Clinical Pharmacology & Therapeutics
The new article “Dose Selection for DuoBody®-CD40x4-1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data” has been recently published in CPT: Clinical Pharmacology & Therapeutics
|
31
| |
Thank you for your message! We will get back to you shortly.
